初创公司 Generation Lab 推出了一款名为 1-Generation 的注射药物组合，宣称该疗法能阻断血液中衰老的系统性传播并恢复组织年轻状态 1。公司首席执行官 Alina Su 称其为“人体首个长寿治疗药物” 1。该疗法基于加州大学伯克利分校退休教授 Irina Conboy 此前关于异时联体共生（parabiosis）和血浆置换的研究开发，Conboy 已于 2025 年从伯克利退休并全职加入该公司担任科学创始人 1。
Generation Lab 目前拒绝公开该组合中两种药物的具体名称，称此举是为了避免被模仿 1。公司计划开展一项涉及 100 人以上的临床试验，但受试者需付费参加 1。此次临床试验将由 BioReset Medical 创始人 Matt Cook 等替代医学医生主导，而 Matt Cook 曾推荐过被美国食品药品监督管理局（FDA）认定为“欺诈性”的新冠疗法 1。此外，Generation Lab 将于 8 月 28 日举办一场仅限邀请的活动，哈佛合成生物学家 George Church 等人受邀出席 1。若 FDA 流程证明该现有药物组合有新用途，公司可获得约三年的独占期 1。
The startup Generation Lab has introduced an injectable drug combination named 1-Generation, claiming it can block the systemic spread of aging in the blood and restore tissues to a youthful state 1. Chief Executive Officer Alina Su described the treatment as "the first longevity therapeutic for humans" 1. However, the company has refused to disclose the specific names of the two drugs involved, stating that this secrecy is intended to prevent imitation 1. This approach has sparked skepticism from the scientific community regarding the company's evidentiary standards and commercial motives 1.
The company's scientific founder, Irina Conboy, previously conducted research on parabiosis and plasma exchange at the University of California, Berkeley 1. She retired from Berkeley in 2025 and joined Generation Lab full-time 1. The company plans to conduct a clinical trial involving more than 100 participants, but subjects will be required to pay to participate 1. The trial will be led by alternative medicine practitioners, including Matt Cook, founder of BioReset Medical, who previously recommended a COVID-19 treatment that the FDA identified as "fraudulent" 1.
Additionally, Generation Lab is scheduled to host an invite-only event on August 28, with attendees including Harvard synthetic biologist George Church 1. Regarding regulatory prospects, if the FDA process determines that the existing drug combination has a new use, the company could be granted an exclusivity period of approximately three years 1.
评论
还没有评论，欢迎留下第一条。